📈
📈 Business
Moderna shares surge 177% after mRNA melanoma vaccine clinical success
Moderna's shares surged nearly 177% on Wall Street in a single trading session after the company reported a clinical success for its mRNA-based melanoma vaccine. Investors trading options on the stock recorded returns approaching one million percent. It marks one of the largest single-day gains in the company's history.
Comments
No comments yet
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!